Announcement • Mar 20
PAO Group, Inc. Announces Resignation of James Schramm as Chief Executive Officer, Effective March 18, 2026 PAO Group, Inc. announced that James Schramm has resigned as Chief Executive Officer and that the Purchase and Sale Agreement dated July 21, 2025 has been formally rescinded, effective March 18, 2026, pursuant to a mutual agreement between Mr. Schramm and PAO Group, Inc. Under the terms of the rescission, Law90, LLC will be returned to James Schramm, and Mr. Schramm will return 3,510,000 Preferred C shares of PAO Group, Inc. to James C. DiPrima. Mr. Schramm intends to convey Law90, LLC to Green Stream Holdings, Inc. (“GSFI”). Law90, LLC is a Company which refers cases to attorneys which are members of Law90, LLC. The Company remains focused on advancing its strategic initiatives, strengthening operational continuity, and positioning PAOG for long-term growth. Additional updates regarding leadership and corporate developments will be provided as appropriate. Announcement • Jun 22
PAO Group, Inc. Confirms CBD Nutraceuticals Business Development Update to Include ALKM, USMJ and PURA Highlights Scheduled on June 23, 2021 PAO Group, Inc. confirmed CBD Nutraceuticals Business Development Update on June 23, 2021. PAOG plans to launch a CBD Nutraceuticals line of products expected to generate revenue this year, in 2021, is on track. The company also continues in the long-term CBD pharmaceutical. The 2020 CBD Nutraceuticals Market had an estimated value of $5.2 Billion, and it is expected to reach $16.4 Billion by 2027. PAOG is working on the development of a CBD pharmaceutical product under the name RespRx, for the treatment of Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT." PAOG plans to develop and distribute its CBD nutraceuticals with Alkame Holdings, Inc. (OTC Pink: ALKM) as a copacker and North American Cannabis Holdings, Inc. (OTC Pink: USMJ) as a distributor. The update on Wednesday will include highlights on ALKM and USMJ roles in PAOG’s CBD Nutraceuticals Business Development. The update will also include an update on the intended distribution of PAOG stock to PURA (OTC Pink: PURA) shareholders in conjunction with PAOG’s acquisition of PURA’s cannabis cultivation operation. Announcement • Jun 18
PAOG Plans to Launch CBD Nutraceuticals Line of Products PAO Group, Inc. confirmed the company’s plan to launch a CBD Nutraceuticals line of products expected to generate revenue this year, in 2021, is on track. The company also continues in the long-term CBD pharmaceutical. Next week, on June 23, management will release an update on the company’s CBD Nutraceuticals development initiative to include new developments expected to expand company’s overall market opportunity. The company is working on the development of a CBD pharmaceutical product under the name RespRx, for the treatment of Chronic Obstructive Pulmonary Disorder derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT. 
